PharmApprove Leaders To Present on FDA Advisory Committee Preparedness at Washington, DC Conference
Washington, D.C. (PRWEB) February 05, 2014 -- Two leaders from PharmApprove – the leading strategic, regulatory and scientific communication consultancy to the pharmaceutical and biotechnology industries – will present this week at the 5th Annual “Effective Preparation for FDA Advisory Committee Meetings” conference organized by CBI, on Thursday, February 6th. Pete Taft, founder and CEO, and Dr. Laurie Smaldone, President, will lead an Interactive Mock FDA Advisory Committee Meeting for conference-goers.
Taft, a communications consultant and former journalist, founded PharmApprove in 1999, in order to help pharmaceutical clients successfully face regulatory committees convened by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Smaldone, PharmApprove President since 2011, has 25 years of leadership experience in drug development, regulatory strategy, and regulatory approvals across all major therapeutic areas and product technologies.
Taft and Smaldone will offer insights on how participants can prepare for an Advisory Committee, and showcase best practices for facing tough questions. Later at the conference, Taft will moderate a discussion on “Improving and Optimizing Vendor Selection.”
CBI, an Advanstar company, is a life sciences industry leader in providing conference platforms that facilitate innovation, collaboration and elevation across the pharmaceutical, biotechnology, medical device and healthcare industries.
About PharmApprove:
PharmApprove is the leading strategic, regulatory, and scientific communications consultancy to the pharmaceutical and biotech industries. The firm offers both strategic and tactical support to companies facing high-profile, high stakes events and engagements anywhere along the road to approval and commercialization, helping them win health authority approvals, deliver compelling regulatory communications, and make persuasive pharmacoeconomic arguments to payers and HTAs. Learn more at http://www.pharmapprove.com.
Rachel Darwin, PharmApprove, http://www.pharmapprove.com, +1 (609) 683-0700, [email protected]
Share this article